1832 Asset Management
CRDL

1832 Asset Management’s Cardiol Therapeutics CRDL Stock Holding History

1832 Asset Management’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$106K Hold
100,000
– – ﹤0.01% 628
2026
Q1 		$135K Hold
100,000
– – ﹤0.01% 645
2025
Q4 		$95.4K Buy
+100,000
New +$105K ﹤0.01% 686

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

1832 Asset Management's CRDL Position: Q2 2026 in Review

1832 Asset Management held its Cardiol Therapeutics (CRDL) position steady in Q2 2026 at 100,000 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #628.

1832 Asset Management first reported a position in CRDL in Q4 2025 and has held it in 3 quarters since. The position peaked at $135K in Q1 2026. 51 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

  • 1832 Asset Management held 100,000 shares of Cardiol Therapeutics worth $106K as of Q2 2026.
  • 1832 Asset Management left its Cardiol Therapeutics share count unchanged in Q2 2026.
  • Cardiol Therapeutics made up ﹤0.01% of 1832 Asset Management's portfolio in Q2 2026, its #628 holding.
  • 1832 Asset Management first reported a position in Cardiol Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 1832 Asset Management's Cardiol Therapeutics position peaked at $135K in Q1 2026.
  • 51 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on 1832 Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.